Skip Navigation

Adalvo Submits Three Different INN DCPs In Under 24 Hours

09 August 2023

Adalvo is proud to share a significant achievement in our pursuit to making a difference for patients around the world. Last week, the company successfully filed three distinct INN DCP applications for Azelastine+Fluticasone Nasal Spray, Adapalene/ Benzoyl peroxide, and Dapagliflozin, all within one day.

This remarkable achievement exemplifies Adalvo's strong market access capabilities and the exceptional teamwork that drives our company forward. The simultaneous filing of these INN DCPs showcases Adalvo's commitment to always being on target and our unwavering dedication to providing cutting-edge solutions to our esteemed partners.

Reflecting on this achievement, Anil Okay, CEO of Adalvo, remarked, "We are thrilled to see our teams come together with unparalleled synergy to accomplish such a significant milestone. This accomplishment is a testament to Adalvo's relentless pursuit of excellence and our collective drive to make a meaningful impact on healthcare."

With a vision firmly rooted in becoming the preferred partner, Adalvo remains dedicated to driving a positive change in the pharmaceutical industry by setting a new standard for the future of pharma.

Partner up now!  
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward. – Central & Eastern Europe, Russia & CIS - LATAM (exc. Brazil) North Europe, APAC, MENA & Israel – Brazil - LATAM (exc. Brazil) & South Europe – Europe – UK/Ireland, North America & South Africa - Head of Global BD&L

Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.